Corvex, Inc., an AI computing platform specializing in GPU-accelerated infrastructure, will announce its Q3 2026 financial results on November 12 before market open. The company will host a live webcast and conference call at 8:30 a.m. ET to discuss the results and provide a business update, including a Q&A session. Investors can submit questions in advance via email and access the webcast replay on Corvex's investor relations website. This event is important for investors to gauge Corvex's performance and outlook in the AI cloud computing sector.
Corvex's upcoming Q3 2026 earnings call is scheduled for November 12. For readers following the Technology sector, here is Pluang's market snapshot as of Nov 04, 2026 03:41 WIB: out of 150 priced US stocks, 94 rose and 53 fell. Notable movers include CRDO at USD 152.37 (+8.82%), GRAB at USD 3.11 (+8.74%), and AXTI at USD 52.12 (+8.13%).
Nova Klúbburinn hf. has completed a share buyback program, acquiring 122,699,386 shares at an average price of ISK 3.26 per share. The buyback was part of an inverse offer process with valid bids for 159,526,476 shares. The company accepted bids up t...
AMC Entertainment will release its Q3 2026 earnings on Nov. 4, following a year-over-year increase in North American box-office receipts to about $3.1 billion from $2.5 billion in Q3 2025. The quarter featured major film releases like Spider-Man: Bra...
Pomerantz LLP is investigating Erasca, Inc. following the termination of its COO, Nicholas Chetwyn, which led to a nearly 10% drop in the company's stock price. The investigation focuses on whether Erasca and its executives engaged in securities frau...
Pomerantz LLP is investigating claims against Yiren Digital Ltd. for possible securities fraud following the company's disclosure of a 34% revenue decline and a significant net loss in Q4 2025. The company also reported increased delinquency rates an...
Pomerantz LLP is investigating Syndax Pharmaceuticals following the company's announcement that its Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis failed to meet its primary endpoint. This news caused Syndax's stock to drop by 2.59% on...
